Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares
Launched by DARTMOUTH-HITCHCOCK MEDICAL CENTER · Apr 4, 2018
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hospitalized patients with known or newly diagnosed moderate to severe ulcerative colitis (as defined by the Mayo score ≥6)
- • Consented within the first 48 hours of initiating IV steroids
- • Risk score of \>3 points (pts)
- • Mean stool frequency/24 hrs (\<4 = 0 pts, 4-6 = 1 pt, 7-9 = 2 pts, \>9 = 4 pts)
- • Colonic Dilation = 4pts
- • Hypoalbuminemia (\< 3mg/dL) = 1 pts
- • Mayo endoscopic sub-score \>2 (moderate to severe)
- • Age \>18 and able to make their own medical decisions
- Exclusion Criteria:
- • Complication requiring urgent surgical intervention (in the opinion of the investigators)
- * Clinically significant cardiac, renal, neurological, endocrine, respiratory or hepatic impairment in the opinion of the investigator, including but not limited to:
- • Pulmonary (COPD with CO2 retention; Previous/current imaging showing hyperinflation/air trapping/bullous disease/blebs (opinion of investigators), Current pneumothorax or previous spontaneous pneumothorax, Bronchogenic cyst(s))
- • Cardiac (Uncontrolled HTN (systolic \>160 or diastolic \>100), Unstable angina or myocardial infarction within the previous 3 months, Ejection fraction \< 35%, Current or previous amiodarone use, ICD in place, Pacemaker in place not approved for chamber use)
- • Hematological/Oncological (Current chemotherapeutic drug use, and past history of bleomycin use,Hereditary Spherocytosis, Sickle cell anemia)
- • Gastrointestinal and Infectious Disease (Known or suspected Crohn's disease, Previous infection with mycobacterium, fungus, HIV, Hepatitis B or C, Severe gastrointestinal or systemic infection (opinion of investigator), Current capsule endoscopy or previously non-retrieved capsule
- • Endocrinology (Uncontrolled hyperthyroidism)
- • Neurological and Psychological (Vagal or other nerve stimulators, Uncontrolled seizure disorder, Medications or medical conditions that lower seizure threshold (opinion of the investigator), Drug or alcohol abuse/dependence,Current treatment for alcohol cessation with disulfiram, Current or recent (within past week) use of baclofen)
- • Head and Neck (Previous middle ear damage, surgery or infection(s) which may increase the risk for needing ear tubes (opinion of the investigator),Current or previous retinal detachment or optic neuritis, Retinal or vitreous surgery within the past 3 months)
- • Implanted devices not on the approved list for use with HBOT
- • Women who are pregnant or nursing. Women with childbearing potential were required to use effective birth control if not surgically sterile or postmenopausal for \>2 years.
About Dartmouth Hitchcock Medical Center
Dartmouth-Hitchcock Medical Center (DHMC) is a leading academic medical institution located in Lebanon, New Hampshire, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a major teaching hospital affiliated with the Geisel School of Medicine at Dartmouth, DHMC integrates cutting-edge clinical trials and translational research into its comprehensive patient care approach. The center emphasizes collaboration across disciplines, aiming to enhance patient outcomes through rigorous scientific investigation, education, and community engagement. With a focus on ethical practices and patient safety, DHMC is dedicated to contributing to the advancement of medical knowledge and improving health care delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Baltimore, Maryland, United States
San Diego, California, United States
Dallas, Texas, United States
Lebanon, New Hampshire, United States
New York, New York, United States
La Jolla, California, United States
Yakima, Washington, United States
Patients applied
Trial Officials
Parambir Dulai, MD
Principal Investigator
University of California, San Diego
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials